



# HOKKAIDO UNIVERSITY

Title	Species identification of $\beta$ -hemolytic streptococci from diseased companion animals and their antimicrobial resistance patterns in Japan (2021)
Author(s)	Kurita, Goro; Tsuyuki, Yuzo; Shibata, Sachiko et al.
Citation	Japanese Journal of Veterinary Research, 70(1), 19-28
Issue Date	2022-02
DOI	<a href="https://doi.org/10.14943/jjvr.70.1.19">https://doi.org/10.14943/jjvr.70.1.19</a>
Doc URL	<a href="https://hdl.handle.net/2115/84411">https://hdl.handle.net/2115/84411</a>
Type	departmental bulletin paper
File Information	JJVR70-1_19-28_GoroKurita.pdf



# Species identification of $\beta$ -hemolytic streptococci from diseased companion animals and their antimicrobial resistance patterns in Japan (2021)

Goro Kurita<sup>1)</sup>, Yuzo Tsuyuki<sup>1,2)</sup>, Sachiko Shibata<sup>3)</sup>, Megumi Itoh<sup>2)</sup>,  
Mieko Goto<sup>1)</sup>, Haruno Yoshida<sup>1)</sup> and Takashi Takahashi<sup>1,\*)</sup>

<sup>1)</sup>Laboratory of Infectious Diseases, Graduate School of Infection Control Sciences & Ōmura Satoshi Memorial Institute, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641, Japan

<sup>2)</sup>Division of Clinical Laboratory, Sanritsu Zelkova Veterinary Laboratory, 3-5-5 Ogibashi, Koto-ku, Tokyo 135-0011, Japan

<sup>3)</sup>Division of Clinical Laboratory, Sanritsu Laboratory, 1353-25 Kamikouya, Yachiyo, Chiba 276-0022, Japan

Received for publication, October 11, 2021; accepted, January 4, 2022

## Abstract

We aimed to identify species and evaluate antimicrobial resistance (AMR) of  $\beta$ -hemolytic streptococci recovered from Japanese companion animals in 2021. Strains were recovered from clinical specimens of 109 companion animals that exhibited symptoms/signs between April and May, 2021. We identified strains by 16S rRNA sequencing and evaluated their AMR phenotypes using the broth microdilution method. Macrolide/lincosamide/tetracycline resistance genes, including *erm*(A), *erm*(B), and *mef*(A), in addition to *tet*(M), *tet*(O), *tet*(K), *tet*(L), and *tet*(S), were amplified by polymerase chain reaction. The 16S rRNA sequencing identified  $\beta$ -hemolytic streptococcal strains as *Streptococcus canis* ( $n = 102$ , 93.6%), *S. dysgalactiae* subsp. *equisimilis* ( $n = 4$ ), *S. agalactiae* ( $n = 2$ ), and *S. dysgalactiae* subsp. *dysgalactiae* ( $n = 1$ ). Overall AMR rates were 34.9% for minocycline, 22.0% for erythromycin, 22.9% for azithromycin, 21.1% for clindamycin, and 10.1% for levofloxacin. We found macrolide/lincosamide/tetracycline resistance gene detection of *tet*(M) (9.2%), *tet*(O) (26.6%), *tet*(L) (1.8%), *erm*(B) (22.0%), and *mef*(A) (1.8%). Our findings support the unique features of  $\beta$ -hemolytic streptococci from companion animals (dominant *S. canis* isolation and dominant resistance to tetracycline), along with dominant tetracycline resistance genes, in agreement with those of  $\beta$ -hemolytic streptococci in 2017.

Key Words: species identification, antimicrobial resistance,  $\beta$ -hemolytic streptococci, companion animals, Japan

## Introduction

To identify streptococcal strains, cell wall carbohydrate antigen grouping by Lancefield antisera is used, along with the properties of  $\beta$ -/ $\alpha$ -/ $\gamma$ -hemolysis on sheep blood agar

plates in veterinary clinical situations. For example, outside veterinary laboratories (with a microorganism testing room) provide identification results of  $\beta$ -hemolytic groups G/C/B/A streptococci to veterinarians. In a previous study<sup>6)</sup>, we reported species-level identification of

\* Corresponding author:

Prof. Takashi Takahashi

Laboratory of Infectious Diseases, Graduate School of Infection Control Sciences & Ōmura Satoshi Memorial Institute, Kitasato University

5-9-1 Shirokane, Minato-ku, Tokyo 108-8641, Japan

Tel: +81-3-5791-6428, Fax: +81-3-5791-6441, E-mail: taka2si@lisci.kitasato-u.ac.jp

doi: 10.14943/jjvr.70.1.19

$\beta$ -hemolytic streptococcal strains from diseased companion animals (i.e., dogs and cats), based on 16S rRNA sequencing data. Group G strains included *Streptococcus canis* and *S. dysgalactiae* subsp. *equisimilis*, while group C consisted of *S. dysgalactiae* subsp. *equisimilis*, *S. dysgalactiae* subsp. *dysgalactiae*, and *S. equi* subsp. *zooepidemicus*. Groups B and A strains included only one species for each: *S. agalactiae* and *S. dysgalactiae* subsp. *equisimilis*, respectively. Thus, groups G/C strains possess multiple streptococcal species and their antimicrobial resistance (AMR) data should be evaluated for each species (not for each group).

*S. canis*, which was first reported in 1986<sup>3)</sup>, forms large, smooth, gray-white-colored colonies with strong  $\beta$ -hemolysis on blood agar. It also shows a Christie-Atkins-Munch-Peterson (CAMP) positive reaction as a biochemical property. This bacterium is an emerging pathogen that causes self-limiting dermatitis. However, *S. canis* is associated with multiple documented pyogenic syndromes in cats by an institutional boarding facility<sup>14)</sup>. In some animals, this bacterial infection may lead to severe diseases in companion animals, including arthritis, streptococcal toxic shock syndrome, necrotizing fasciitis, septicemia, and pneumonia<sup>4,11)</sup>. *S. canis*-related invasive infections may be underdiagnosed because species-level identification has not been conducted for the same.

*S. dysgalactiae* subsp. *equisimilis* strains also form large, smooth, gray-white-colored colonies with strong  $\beta$ -hemolysis, which has microbiological properties similar to those of *S. canis*. This bacterium is zoonotic and is transmitted among some animals (i.e., healthy dogs, cats, and horses) and humans<sup>1,17)</sup>. On the other hand, *S. dysgalactiae* subsp. *dysgalactiae* shows a variety of  $\alpha$ - $\beta$ - $\gamma$ -hemolysis, which is mainly recovered from pigs and cows<sup>21)</sup>. Both subspecies indicate  $\beta$ -D-glucuronidase positive reaction as a biochemical property.

*S. agalactiae* strains exhibit  $\beta$ -hemolytic activity, along with a CAMP-positive reaction. This bacterium can grow in milk as well as

in rectal and vaginal specimens<sup>18)</sup> and causes intramammary infections (mastitis) among cows. A recent study demonstrated that *S. agalactiae* clones were shared by cows and herdspersons<sup>18)</sup>. This microorganism is a part of the host commensal flora in the urogenital and lower gastrointestinal tracts in 10%–40% of healthy human adults<sup>5)</sup>. Thus, human and veterinary clinicians should be aware of the potential risk of infectious diseases caused by this bacterium.

We documented significant changes in AMR rates among *S. canis* strains recovered in 2017 and 2015<sup>6)</sup>. Tetracycline and macrolide/lincosamide resistance rates seem to have increased rapidly among *S. canis* strains in Japan. The prevalence of tetracycline resistance was 41.0% vs. 22.1% ( $P = 0.01$ ), the prevalence of macrolide resistance 18.3% vs. 5.9% ( $P = 0.016$ ), and the prevalence of lincosamide resistance 17.1% vs. 5.9% ( $P = 0.039$ ). According to a report from the National Veterinary Assay Laboratory<sup>13)</sup>, quinolone and tetracycline antimicrobials constituted 7.0% and 1.9% of the overall antibiotics (converted weight in kilograms to bulk powder) used for dogs and cats in 2016. Therefore, we need to monitor the changes in AMR rates among  $\beta$ -hemolytic streptococci, in particular *S. canis*, in the future.

Few studies have assessed all  $\beta$ -hemolytic streptococci from diseased dogs/cats in Japan in terms of species-level identification and their AMR phenotypes or macrolide/lincosamide/tetracycline resistance genotypes. The purpose of this study was to determine the species-level identification and AMR patterns of  $\beta$ -hemolytic streptococcal strains recovered from companion animals in 2021.

## Materials and Methods

### Collecting $\beta$ -hemolytic streptococcal strains and host information

Clinical specimens (submitted by veterinarians), along with culture request sheets (including host information), were immediately






Fig. 1.

Japanese geographical distribution of clinical specimens collected between April and May in 2021, to recover  $\beta$ -hemolytic streptococcal strains from diseased dogs and cats. The main prefectures were Tokyo ( $n = 42$ ), Chiba ( $n = 23$ ), Saitama ( $n = 11$ ), Aichi ( $n = 10$ ), and Kanagawa ( $n = 8$ ). The specimens were from sterile sites ( $n = 8$ ), whereas those were from non-sterile sites ( $n = 101$ ).

meropenem, minocycline, erythromycin, azithromycin, clindamycin, levofloxacin, vancomycin, and chloramphenicol) were examined using broth microdilution method (MICroFAST Panel Type 7J for *Streptococcus* spp., Beckman Coulter Inc., Tokyo, Japan) as previously described<sup>6)</sup>, according to the Clinical and Laboratory Standards Institute (CLSI) guidelines for  $\beta$ -hemolytic streptococci<sup>2)</sup>. When determining minocycline resistance, we used the tetracycline breakpoint in accordance with CLSI guidelines. The quality of antimicrobial susceptibility testing was controlled using two American Type Culture Collection (ATCC) strains (*Enterococcus faecalis* ATCC 29212 and *S. pneumoniae* ATCC 4961). The AMR rate and MIC values were measured for

each  $\beta$ -hemolytic streptococcal strain against the antimicrobial agents. We also calculated the lowest antimicrobial concentrations at which 50% (MIC<sub>50</sub>) and 90% (MIC<sub>90</sub>) of each species were inhibited.

The presence of macrolide/lincosamide resistance genes [*erm*(A), *erm*(B), and *mef*(A)], in addition to tetracycline resistance genes [*tet*(M), *tet*(O), *tet*(K), *tet*(L), and *tet*(S)] among all  $\beta$ -hemolytic streptococcal strains was confirmed by PCR<sup>7,12)</sup>. The correct sequences of these resistance genes from several PCR-positive strains were confirmed via direct sequencing analysis of purified amplicons. The significance of differences between AMR phenotypes and macrolide/lincosamide/tetracycline resistance genotypes in 2021 and 2017 were assessed.

**Table 2.** Species/subspecies ID of dog/cat-origin  $\beta$ -hemolytic streptococci based on 16S rRNA sequencing data according to cell wall carbohydrate antigenicity

Lancefield group	ID data of the streptococci isolated in 2021	ID data of the streptococci isolated in 2017
G	<i>S. canis</i> (93.6%), <i>S. dysgalactiae</i> subsp. <i>equisimilis</i> (0.9%) <sup>1)</sup>	<i>S. canis</i> (89.3%), <i>S. dysgalactiae</i> subsp. <i>equisimilis</i> (1.5%)
C	<i>S. dysgalactiae</i> subsp. <i>equisimilis</i> (2.8%) <sup>1)</sup>	<i>S. dysgalactiae</i> subsp. <i>equisimilis</i> (1.5%), <i>S. dysgalactiae</i> subsp. <i>dysgalactiae</i> (0.8%), <i>S. equi</i> subsp. <i>zooepidemicus</i> (0.8%)
B	<i>S. agalactiae</i> (1.8%)	<i>S. agalactiae</i> (5.3%)
A	<i>S. dysgalactiae</i> subsp. <i>dysgalactiae</i> (0.9%) <sup>2)</sup>	<i>S. dysgalactiae</i> subsp. <i>equisimilis</i> (0.8%)
Total no. (%)	109 (100%)	131 (100%)

ID, identification. The parentheses indicate the percentages of species/subspecies ID among the total streptococci. We cited ID data of the streptococci isolated in 2017 from our previous study (6).

<sup>1)</sup> Four strains of *S. dysgalactiae* subsp. *equisimilis* possessed *stG840.0*, *stC9431.0*, *stC37.0*, and *stL1929.1*.

<sup>2)</sup> One strain of *S. dysgalactiae* subsp. *dysgalactiae* possessed *stC46.2* (GenBank accession no. LC649931).

### Ethical statement

The Ethics Committee at the Sanritsu Zelkova Veterinary Laboratory reviewed and approved the study design (approval number SZ20210825) to ensure the privacy of affected dogs and cats.

### Statistical analysis

We used Fisher's exact probability test (two-sided) to assess significant differences in categorical variables between data obtained in 2021 and 2017. Statcel4 application (OMS Publisher, Tokyo, Japan) was used for this analysis. Statistical significance was set at  $P < 0.05$ .

## Results

### $\beta$ -hemolytic streptococcal strains and host information

Of the 2,112 clinical specimens obtained from the dogs ( $n = 1,464$ ) and cats ( $n = 648$ ), 109  $\beta$ -hemolytic streptococcal strains (isolation rate 5.2%), including groups G ( $n = 103$ ), C ( $n = 3$ ), B ( $n = 2$ ), and A ( $n = 1$ ), were collected from April 1<sup>st</sup>, 2021 through May 31<sup>st</sup>, 2021. Fig. 1 shows the geographical distribution of clinical specimens collected during the study period. The prefectures sampled were Tokyo ( $n = 42$ ), Chiba ( $n = 23$ ), Saitama ( $n = 11$ ), Aichi ( $n = 10$ ), Kanagawa ( $n = 8$ ), Ibaraki ( $n = 3$ ), and Miyagi/Tochigi/Gifu ( $n =$

2 for each). Strains were obtained from sterile specimens of uterine content ( $n = 7$ ) and ascites ( $n = 1$ ). There were also those obtained from open pus ( $n = 36$ ), ear/nose-origin ( $n = 28$ ), urogenital tracts-derived ( $n = 24$ ), eye-origin ( $n = 9$ ), anal glandular fluid ( $n = 2$ ), and other specimens ( $n = 2$ ) of dogs ( $n = 98$ ) and cats ( $n = 11$ ). The companion animal demographics were as follows: mean age, 10.9 years; age range, 1–17 years; sex, 50 males and 59 females.

### Identification by 16S rRNA sequencing

Table 2 indicates the species/subspecies identification of  $\beta$ -hemolytic streptococci based on 16S rRNA sequencing data according to the Lancefield group. A total of 109 streptococcal strains consisted of *S. canis* ( $n = 102$ , 93.6%) belonging to group G, *S. dysgalactiae* subsp. *equisimilis* ( $n = 4$ , 3.7%) belonging to groups C and G, *S. agalactiae* ( $n = 2$ , 1.8%) belonging to group B, and *S. dysgalactiae* subsp. *dysgalactiae* ( $n = 1$ , 0.9%) belonging to group A. There was no significant difference in the prevalence between different species identified in 2021 and 2017.

### Evaluation of identification validity

All *S. canis* strains possessed the specific *cfg*, and two *S. agalactiae* strains contained the specific *dltS*. Four *S. dysgalactiae* subsp. *equisimilis* strains included *emm* genotypes of *stG840.0*, *stC9431.0*, *stC37.0*, and *stL1929.1*. One

**Table 3.** Antimicrobial resistance phenotypes and macrolide/lincosamide/tetracycline resistance genotypes among  $\beta$ -hemolytic streptococcal strains in 2021/2017

Resistance phenotype and genotype	Percentage of $\beta$ -hemolytic streptococcal strains in 2021 ( $n = 109$ )	Percentage of $\beta$ -hemolytic streptococcal strains in 2017 ( $n = 131$ )
Resistance to minocycline	34.9 ( $n = 38$ )	39.7 ( $n = 52$ )
Resistance to erythromycin	22.0 ( $n = 24$ )	19.8 ( $n = 26$ )
Resistance to azithromycin	22.9 ( $n = 25$ )	19.8 ( $n = 26$ )
Resistance to clindamycin	21.1 ( $n = 23$ )	17.6 ( $n = 23$ )
Resistance to levofloxacin	10.1 ( $n = 11$ )	4.6 ( $n = 6$ )
<i>tet</i> (M)	9.2 ( $n = 10$ )	16.0 ( $n = 21$ )
<i>tet</i> (O)	26.6 ( $n = 29$ )	29.8 ( $n = 39$ )
<i>tet</i> (L)	1.8 ( $n = 2$ )	2.3 ( $n = 3$ )
<i>tet</i> (S)	0	2.3 ( $n = 3$ )
<i>erm</i> (B)	22.0 ( $n = 24$ )	18.3 ( $n = 24$ )
<i>mef</i> (A)	1.8 ( $n = 2$ )	3.8 ( $n = 5$ )

Antimicrobial resistance was determined based on the Clinical and Laboratory Standards Institute (CLSI) guidelines (M100-S25).

When determining resistance to minocycline, we used the tetracycline breakpoint in accordance with CLSI guidelines.

We cited resistance data of streptococci isolated in 2017 from our previous study <sup>6</sup>.

*S. dysgalactiae* subsp. *dysgalactiae* strain had an *emm* genotype of *stC46.2* (GenBank accession no. LC649931).

#### **AMR phenotypes and macrolide/lincosamide/tetracycline resistance genotypes**

The prevalence of antimicrobial resistance and resistance genes among  $\beta$ -hemolytic streptococcal strains in 2021 are shown in Table 3. Overall AMR rates were 34.9% ( $n = 38$ ) for minocycline, 22.0% ( $n = 24$ ) for erythromycin, 22.9% ( $n = 25$ ) for azithromycin, 21.1% ( $n = 23$ ) for clindamycin, and 10.1% ( $n = 11$ ) for levofloxacin. There were no significant differences between the rates of resistance to the five antimicrobials in 2021 and those in 2017. None of the strains were resistant to  $\beta$ -lactams (including meropenem) and vancomycin: one strain was non-susceptible to chloramphenicol (MIC 8  $\mu\text{g}/\text{mL}$ ). We found MIC<sub>50</sub>/MIC<sub>90</sub> of minocycline ( $1/>4$   $\mu\text{g}/\text{mL}$ ), erythromycin ( $<0.12/>2$   $\mu\text{g}/\text{mL}$ ), azithromycin ( $<0.25/>4$   $\mu\text{g}/\text{mL}$ ), clindamycin ( $<0.12/>1$   $\mu\text{g}/\text{mL}$ ), and levofloxacin ( $0.5/>8$   $\mu\text{g}/\text{mL}$ ) against *S. canis* strains ( $n = 102$ ). Thirty-eight minocycline-resistant strains were either *S. canis* ( $n = 35$ ), *S. agalactiae* ( $n = 2$ ), or *S. dysgalactiae* subsp. *equisimilis* ( $n = 1$ ). These minocycline-resistant strains also exhibited

macrolide/lincosamide and/or quinolone resistance, except for one strain that showed only macrolide/lincosamide resistance. Thirty-nine resistant strains were recovered from sterile (uterine content,  $n = 3$ ) and non-sterile (open pus, ear/nose-origin, eye-origin, urogenital tracts-origin, tooth-origin, and skin-origin,  $n = 36$ ) sites and were confirmed in nine of 15 prefectures.

We found the macrolide/lincosamide/tetracycline resistance genes *tet*(M) ( $n = 10$ , 9.2%), *tet*(O) ( $n = 29$ , 26.6%), *tet*(L) ( $n = 2$ , 1.8%), *erm*(B) ( $n = 24$ , 22.0%), and *mef*(A) ( $n = 2$ , 1.8%). There was no amplification of either *tet*(K), *tet*(S), or *erm*(A) among the strains. We observed no significant differences between the rates of detection of resistance genes in 2021 and of those in 2017. *S. canis* included 37 (36.3%) strains with these resistance genes. Forty-one strains with resistance genes were recovered from sterile ( $n = 3$ ) and non-sterile ( $n = 38$ ) sites and were confirmed in nine of 15 prefectures.

#### **Discussion**

Of the 109  $\beta$ -hemolytic streptococci, we identified four different species/subspecies (*S.*

**Table 4.** Changes in resistance rates among *S. canis* strains from 2021, 2017, and 2015

Antimicrobial	Resistance rate (%) in 2021 ( <i>n</i> = 102)	Resistance rate (%) in 2017 ( <i>n</i> = 117)	Resistance rate (%) in 2015 ( <i>n</i> = 68)
Tetracycline	34.3 ( <i>n</i> = 35)	41.0 ( <i>n</i> = 48)	22.1 ( <i>n</i> = 15)
Macrolide	22.5 ( <i>n</i> = 23)	18.8 ( <i>n</i> = 22)	5.9 ( <i>n</i> = 4)
Lincosamide	15.6 ( <i>n</i> = 16)	17.1 ( <i>n</i> = 20)	5.9 ( <i>n</i> = 4)
Quinolone	10.8 ( <i>n</i> = 11)	3.4 ( <i>n</i> = 4)	4.4 ( <i>n</i> = 3)

Antimicrobial resistance was determined based on the Clinical and Laboratory Standards Institute (CLSI) guidelines (M100-S25/M100-S22).

When determining resistance to minocycline, we used the tetracycline breakpoint in accordance with CLSI guidelines.

We cited resistance data of streptococci recovered from our previous studies <sup>6,22</sup>.

*canis* belonging to group G, *S. dysgalactiae* subsp. *equisimilis* belonging to groups C and G, *S. agalactiae* belonging to group B, and *S. dysgalactiae* subsp. *dysgalactiae* belonging to group A). In contrast, the following five species and subspecies were identified in our previous study<sup>6</sup>: *S. canis* (group G), *S. agalactiae* (group B), *S. dysgalactiae* subsp. *equisimilis* (groups C, G, and A), *S. dysgalactiae* subsp. *dysgalactiae* (group C), and *S. equi* subsp. *zoepidemicus* (group C). In agreement with these observations, the prevalent streptococcal strains recovered from dogs in the USA were *S. canis*, *S. dysgalactiae* subsp. *equisimilis*, and *S. equi* subsp. *zoepidemicus*<sup>11</sup>. We need to collect and analyze more  $\beta$ -hemolytic streptococci recovered from dog/cat-derived clinical specimens to confirm the variations of the isolation and AMR rates.

Four *emm* genotypes (*stG840.0*, *stC9431.0*, *stC37.0*, and *stL1929.1*) were detected in the *S. dysgalactiae* subsp. *equisimilis* strains in the 2021-investigation. Additionally, three *emm* types (*stC9431.0*, *stG245.0*, and *stG485.0*) were observed in 2017<sup>6</sup>, and two *emm* types (*stC9431.0*, *stG6792.3*, and *stC1929.1*) were found in 2015<sup>22</sup>. These *emm* genotypes seem to contribute to the understanding of the transmission profiles of *S. dysgalactiae* subsp. *equisimilis* between dogs/cats and humans, although these studies had small numbers of strains. We should further increase the *emm* genotype data in the animal-derived *S. dysgalactiae* subsp. *equisimilis*.

Table 4 shows the changes in resistance rates among *S. canis* strains from 2021, 2017<sup>6</sup>, and 2015<sup>22</sup> because of the dominant *S. canis* isolation

among  $\beta$ -hemolytic streptococci from 2021. Three investigations revealed the dominant resistance to tetracycline. Therefore, Japanese veterinarians should be informed of the necessity of careful administration of tetracycline in practice.

We constructed draft genome sequences of seven *S. canis* strains from dogs and cats that were collected during the study period of April–May 2017<sup>23</sup>. The resistance genotypes were determined by inserting our contig sequences into the Web-based application ResFinder version 3.2 (<https://cge.cbs.dtu.dk/services/ResFinder/>), which is managed by the Center for Genomic Epidemiology<sup>24</sup>. Although there were no macrolide/lincosamide/tetracycline resistance genes in the four strains, we found *tet(S)*, *erm(B)*, and *erm(B)+tet(O)* in the three strains, showing the same resistance genotyping data by PCR. In addition, we found the *erm(B)* variant sequence of *S. agalactiae* clindamycin-resistant erythromycin-susceptible strain based on whole genome sequences, not direct sequencing data with purified amplicons by PCR<sup>19</sup>. This variant sequence contained the insertion of an IS1216E element at nucleotide position 642, which resulted in the deletion of a segment spanning nucleotides 642–738 (97 bp). To confirm the validity of resistance genotyping data by PCR in 2021, we needed to construct whole genome sequences of the 2021-streptococcal strains. It would be better if we could obtain the complete circular genome sequences containing plasmid(s) by conducting both Illumina sequencing (using MiSeq) for short-reads and Nanopore sequencing (using MinION) for long-reads, followed by the hybrid assembly

(using Unicycler)<sup>9)</sup>.

Our study has two limitations. First, this investigation had limited host information (species, sex, age, clinical specimen, bacterial isolation date, and prefecture in which veterinarians worked). In future investigations, detailed information, in particular antimicrobial dosing used for the animals, needs to be collected from veterinarians to estimate the antimicrobial selective pressure. Second, the number of strains from sterile sites of uterine content ( $n = 7$ ) and ascites ( $n = 1$ ) was small. We experienced severe soft tissue infection with septic shock caused by *S. canis* isolated from the blood/necrotic tissue of a miniature dachshund<sup>15)</sup>. Further investigation including sterile specimens from severe diseases should be conducted to understand the situations of severe infections (streptococcal toxic shock syndrome, severe soft tissue infection, etc.).

In conclusion, our findings support dominant *S. canis* isolation and dominant resistance to tetracycline, along with dominant tetracycline resistance genes among  $\beta$ -hemolytic streptococcal strains from diseased dogs and cats in Japan (April–May, 2021). These unique features could be useful to Japanese veterinarians when examining and treating animals with clinical symptoms/signs suggestive of streptococcal infections. In the future, these strains should be monitored throughout the country sequentially and additional  $\beta$ -hemolytic streptococcal strains need to be characterized.

#### Acknowledgments

The authors wish to thank Mr. Yasuto Fukushima and Mr. Takahiro Maeda (Laboratory of Infectious Diseases, Graduate School of Infection Control Sciences, Kitasato University, Tokyo, Japan) for their helpful assistances and suggestions and Editage (www.editage.jp) for the English language editing.

#### Conflict of interest

None to declare.

#### References

- 1) Acke E, Midwinter AC, Lawrence K, Gordon SJ, Moore S, Rasiah I, Steward K, French N, Waller A. Prevalence of *Streptococcus dysgalactiae* subsp. *equisimilis* and *S. equi* subsp. *zooepidemicus* in a sample of healthy dogs, cats and horses. *N Z Vet J* 63, 265-271, 2015.
- 2) Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Fifth Informational Supplement. CLSI document M100-S25, Wayne, PA. 2015.
- 3) Devriese LA, Hommez J, Kilpper-Bälz R, Schleifer KH. *Streptococcus canis* sp. nov.: a species of group G streptococci from animals. *Int J Syst Bacteriol* 36, 422-425, 1986.
- 4) DeWinter LM, Prescott JF. Relatedness of *Streptococcus canis* from canine streptococcal toxic shock syndrome and necrotizing fasciitis. *Can J Vet Res* 63, 90-95, 1999.
- 5) Dhanoa A, Karunakaran R, Puthuchery S. Serotype distribution and antibiotic susceptibility of group B streptococci in pregnant women. *Epidemiol Infect* 138, 979-981, 2010.
- 6) Fukushima Y, Tsuyuki Y, Goto M, Yoshida H, Takahashi T. Species identification of  $\beta$ -hemolytic streptococci from diseased companion animals and their antimicrobial resistance data in Japan (2017). *Jpn J Infect Dis* 72, 94-98, 2019.
- 7) Haenni M, Saras E, Bertin S, Leblond P, Madec JY, Payot S. Diversity and mobility of integrative and conjugative elements in bovine isolates of *Streptococcus agalactiae*, *S. dysgalactiae* subsp. *dysgalactiae*, and *S. uberis*. *Appl Environ Microbiol* 76, 7957-7965, 2010.

- 8) Hassan AA, Khan IU, Abdulmawjood A, Lämmler C. Development of PCR assays for detection of *Streptococcus canis*. FEMS Microbiol Lett 219, 209-214, 2003.
- 9) Kim JS, Sakaguchi S, Fukushima Y, Yoshida H, Nakano T, Takahashi T. Complete genome sequences of four *Streptococcus canis* strains isolated from dogs in South Korea. Microbiol Resour Announc 9, e00818-20, 2020.
- 10) Kim S, Byun J-H, Park H, Lee J, Lee HS, Yoshida H, Shibayama A, Fujita T, Tsuyuki Y, Takahashi T. Molecular epidemiological features and antibiotic susceptibility patterns of *Streptococcus dysgalactiae* subsp. *equisimilis* isolates from Korea and Japan. Ann Lab Med 38, 212-219, 2018.
- 11) Lamm CG, Ferguson AC, Lehenbauer TW, Love BC. Streptococcal infection in dogs: a retrospective study of 393 cases. Vet Pathol 47, 387-395, 2010.
- 12) Malhotra-Kumar S, Lammens C, Piessens J, Goossens H. Multiplex PCR for simultaneous detection of macrolide and tetracycline resistance determinants in streptococci. Antimicrob Agents Chemother 49, 4798-4800, 2005.
- 13) Ministry of Agriculture, Forestry and Fisheries. Investigation data concerning total amounts of antibiotics as human antimicrobials that were sold to veterinary institutes for pet animals in 2016. Available at <[http://www.maff.go.jp/nval/yakuzai/pdf/20190819cyousa\\_2.pdf#search](http://www.maff.go.jp/nval/yakuzai/pdf/20190819cyousa_2.pdf#search)>. Accessed December 13, 2021. (In Japanese)
- 14) Morrow BL, McNatt R, Joyce L, McBride S, Morgan D, Tressler C, Mellits C. Highly pathogenic  $\beta$ -hemolytic streptococcal infections in cats from an institutionalized boarding facility and a multi-species comparison. J Feline Med Surg 18, 318-327, 2016.
- 15) Murata Y, Tsuyuki Y, Hayashi D, Murata S, Fukushima Y, Yoshida H, Takahashi T. Severe soft tissue infection with septic shock caused by *Streptococcus canis* sequence type 9 harboring M-like protein allele 1 in a miniature dachshund. Jpn J Vet Res 69, 189-194, 2021.
- 16) Murayama SY, Seki C, Sakata H, Sunaoshi K, Nakayama E, Iwata S, Sunakawa K, Ubukata K; Invasive Streptococcal Disease Working Group. Capsular type and antibiotic resistance in *Streptococcus agalactiae* isolates from patients, ranging from newborns to the elderly, with invasive infections. Antimicrob Agents Chemother 53, 2650-2653, 2009.
- 17) Schrieber L, Towers R, Muscatello G, Speare R. Transmission of *Streptococcus dysgalactiae* subsp. *equisimilis* between child and dog in an Aboriginal Australian community. Zoonoses Public Health 61, 145-148, 2014.
- 18) Sørensen UBS, Klaas IC, Boes J, Farre M. The distribution of clones of *Streptococcus agalactiae* (group B streptococci) among herdspersons and dairy cows demonstrates lack of host specificity for some lineages. Vet Microbiol 235, 71-79, 2019.
- 19) Takahashi T, Maeda T, Lee S, Lee DH, Kim S. Clonal distribution of clindamycin-resistant erythromycin-susceptible (CRES) *Streptococcus agalactiae* in Korea based on whole genome sequences. Ann Lab Med 40, 370-381, 2020.
- 20) Takahashi T, Sunaoshi K, Sunakawa K, Fujishima S, Watanabe H, Ubukata K; Invasive Streptococcal Disease Working Group. Clinical aspects of invasive infections with *Streptococcus dysgalactiae* ssp. *equisimilis* in Japan: differences with respect to *Streptococcus pyogenes* and *Streptococcus agalactiae* infections. Clin Microbiol Infect 16, 1097-1103, 2010.
- 21) Takahashi T, Ubukata K, Watanabe H. Invasive infection caused by *Streptococcus dysgalactiae* subsp. *equisimilis*: characteristics of strains and clinical features. J Infect Chemother 17, 1-10, 2011.
- 22) Tsuyuki Y, Kurita G, Murata Y, Goto M, Takahashi T. Identification of group G streptococcal isolates from companion animals in Japan and their antimicrobial resistance

- patterns. *Jpn J Infect Dis* 70, 394-398, 2017.
- 23) Yoshida H, Fukushima Y, Katayama Y, Tsuyuki Y, Mizutani T, Takahashi T. Draft genome sequences of seven *Streptococcus canis* strains isolated from diseased companion animals in Japan. *Microbiol Resour Announc* 9, e00123-20, 2020.
- 24) Zankari E, Hasman H, Cosentino S, Vestergaard M, Rasmussen S, Lund O, Aarestrup FM, Larsen MV. Identification of acquired antimicrobial resistance genes. *J Antimicrob Chemother* 67, 2640-2644, 2012.